Related Experiment Video
Updated: Apr 30, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
23.7K
[Application of lenalidomide in chronic lymphocytic leukemia]
Wen Lei1, Ke-Shu Zhou1, Yu-Fu Li1
1Department of Hematology, Henan Cancer Hospital, Henan Institute of Hematology, Zhengzhou 450008, Henan Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|April 26, 2014
Summary
Lenalidomide shows promise in treating chronic lymphocytic leukemia (CLL), offering improved response rates and reduced adverse effects compared to traditional chemotherapy. This review highlights lenalidomide
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Chronic lymphocytic leukemia (CLL) incidence is rising, with the microenvironment and immune system implicated in its pathogenesis.
- Current frontline therapies like FCR (fludarabine, cyclophosphamide, rituximab) can impair the immune system, increasing infection risk and worsening prognosis.
- Lenalidomide represents a significant advancement in managing refractory or relapsed CLL.
Purpose of the Study:
- To review the latest research and progress on lenalidomide in treating chronic lymphocytic leukemia (CLL).
- To evaluate the efficacy and safety of lenalidomide, alone and in combination therapies, for CLL patients.
Main Methods:
- Review of recent studies on lenalidomide in CLL treatment.
- Analysis of clinical trial data regarding response rates and adverse events.
- Focus on lenalidomide's role in refractory or relapsed CLL.
Main Results:
- Lenalidomide monotherapy demonstrated overall response rates (ORR) of 32%-47% in relapsed/refractory CLL.
- Combination therapy with lenalidomide and rituximab achieved ORR of 53%-66%.
- Lenalidomide combined with ofatumumab showed improved efficacy and reduced adverse reactions.
Conclusions:
- Lenalidomide offers a promising therapeutic option for chronic lymphocytic leukemia (CLL), particularly in relapsed or refractory cases.
- Combination therapies involving lenalidomide, rituximab, or ofatumumab enhance efficacy and tolerability.
- Monitoring for adverse reactions such as neutropenia, thrombocytopenia, and tumor lysis syndrome is crucial.
